© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
Full-dose anticoagulation treatment for moderately ill COVID-19 patients reduced the need for ventilators.
The ACTIV-2 study aims to determine whether neutralizing antibodies reduce the duration of COVID-19 symptoms.
Vaccines that stimulate immune responses against cancer using the mRNA technology may be fast-acting and cheap to make.
Two Phase III clinical trials are evaluating monoclonal antibodies for people hospitalized with moderate COVID-19.
In Los Angeles County, daily new COVID cases, deaths and hospitalizations have soared beyond their previous highs.
Lies infected America in 2020. The very worst were not just damaging, but deadly.
Agency grants emergency authorization for antibody cocktail given to President Trump.
Arthritis drug Olumiant (baricitinib) can be used in combination with remdesivir.
Recovery and death rates were similar in people treated with the anti-malaria drug or a placebo.
Bamlanivimab is now authorized for nonhospitalized people at high risk for progressing to severe COVID-19.
The antiviral drug is the first treatment for the new coronavirus to be approved in United States.
None of the four drugs tested in the WHO’s Solidarity trial reduced mortality or duration of hospitalization.
The study asks whether certain approved therapies or late-stage investigational drugs show promise against COVID-19.
Black and Latino cancer patients have higher rates of coronavirus infection and hospitalization but are less likely to use telehealth.
The HIV protease inhibitor combination did not speed recovery or reduce the risk of death in a large study.
The treatment reduced coronavirus levels and sped up recovery in a clinical trial.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.